Item 7.01 Regulation FD Disclosure.
On
The information in this Item 7.01, including the exhibit hereto, is being
furnished and shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended. The information contained in this Item 7.01 and in the
accompanying exhibit shall not be incorporated by reference into any filing with
the
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements which can be
identified by words such as: "will," "anticipate," "plan," "may," "implement,"
"continue," "believe" and similar references to future periods. Examples of
forward-looking statements include, among others, statements we make regarding
the potential impacts of the COVID-19 coronavirus pandemic on our personnel,
their communities, and our business, such as delays or disruptions in our
clinical trials, the anticipated timing for the completion of our clinical
trials and announcement of clinical trial results, and interruptions in our
manufacturing, supply chain, and research and development operations.
Forward-looking statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs, expectations
and assumptions regarding the future of our business, future plans and
strategies, anticipated events and trends, and other future conditions. Because
forward-looking statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are difficult to predict
and many of which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements. Therefore,
you should not rely on any of these forward-looking statements. Important
factors that could cause our actual results to differ materially from those
indicated in the forward-looking statements include, among others: (i) our
statements regarding the potential impacts of the coronavirus pandemic on our
business are based on information, guidelines, and governmental actions that are
changing rapidly over time; (ii) the actions we announced to preserve the
integrity of our clinical trials may not be effective and may not be fully
implemented (if at all) due to circumstances beyond our control; (iii) certain
clinical trials in our pipeline are sponsored and operationalized by our
collaboration partners and are subject to the risks and uncertainties of those
partner's policies and procedures that may continue to evolve over time to
address the impact of the coronavirus pandemic; (iv) clinical development has
inherent risks and the risk of failure remains high and failure can unexpectedly
occur at any stage for one or more of the indications being studied prior to
regulatory approval due to lack of sufficient efficacy, safety considerations or
other factors that impact drug development; and (v) certain other important
risks and uncertainties set forth in Nektar's Annual Report on Form 10-K filed
with the
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description 99.1 Communication titled "A Letter from our President & CEO,Howard Robin (updatedApril 1, 2020 )" issued byNektar Therapeutics onApril 2, 2020 . 1
© Edgar Online, source